Pharmacielo Ltd

Company Profile

Pharmacielo Ltd had its IPO on under the ticker symbol PCLOF.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Pharmacielo Ltd has a staff strength of 0 employees.

Stock update

Shares of Pharmacielo Ltd opened at $0.12 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.12 - $0.16, and closed at $0.16.

This is a +15.94% increase from the previous day's closing price.

A total volume of 26,400 shares were traded at the close of the day’s session.

In the last one week, shares of Pharmacielo Ltd have increased by +19.4%.

Pharmacielo Ltd's Key Ratios

Pharmacielo Ltd has a market cap of $20.85 million, indicating a price to book ratio of 4.28 and a price to sales ratio of 7.2514.

In the last 12-months Pharmacielo Ltd’s revenue was $2.93 million with a gross profit of $-4171733 and an EBITDA of $-11105860. The EBITDA ratio measures Pharmacielo Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Pharmacielo Ltd’s operating margin was -382.05% while its return on assets stood at -25.05% with a return of equity of -172.1%.

In Q2, Pharmacielo Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 92.5%.

Pharmacielo Ltd’s PE and PEG Ratio

Forward PE

5.8309

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.08 per share while it has a forward price to earnings multiple of 5.8309 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pharmacielo Ltd’s profitability.

Pharmacielo Ltd stock is trading at a EV to sales ratio of 9.3563 and a EV to EBITDA ratio of -2.9605. Its price to sales ratio in the trailing 12-months stood at 7.2514.

Pharmacielo Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$25.83 million

Total Liabilities

$7.68 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Pharmacielo Ltd ended 2024 with $25.83 million in total assets and $0 in total liabilities. Its intangible assets were valued at $25.83 million while shareholder equity stood at $3.56 million.

Pharmacielo Ltd ended 2024 with $0 in deferred long-term liabilities, $7.68 million in other current liabilities, in common stock, $-189558353.00 in retained earnings and $0 in goodwill. Its cash balance stood at $105459.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $14.59 million.

Pharmacielo Ltd’s total current assets stands at $3.50 million while long-term investments were $369211.00 and short-term investments were $0.00. Its net receivables were $28603.00 compared to accounts payable of $0 and inventory worth $2.25 million.

In 2024, Pharmacielo Ltd's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Pharmacielo Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.16

52-Week High

$0.344

52-Week Low

$0.079

Analyst Target Price

$

Pharmacielo Ltd stock is currently trading at $0.16 per share. It touched a 52-week high of $0.344 and a 52-week low of $0.344. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.12 and 200-day moving average was $0.16 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 397.4% of the company’s stock are held by insiders while 557% are held by institutions.